3 New Strong Buy Ratings from Top-Rated Analysts: 03/19/2026

Here are 3 of the stocks Smart Money is following right now:

• Nature's Sunshine Products (NATR) — Record results fuel unanimous Strong Buy consensus
• Neurocrine Biosciences (NBIX) — Elite analysts back robust pharma pipeline
• Beachbody Company (BODI) — Stunning turnaround delivers nine straight profitable quarters

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

 

A note from our sponsors...

1. Nature's Sunshine Products (NASDAQ: NATR)

Nature's Sunshine Products just posted record-breaking Q4 and full-year 2025 results that crushed estimates — earning it the #1 Zen Rated Stock spot with strong analyst support.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $24.00 — get current quote

Max 1-year forecast: $33.00

Why we're watching:

• Analyst support: Unanimous Strong Buy consensus from 2 analysts covering the stock, both projecting a $33 price target representing 35.64% upside. See the ratings
• Canaccord Genuity analyst Susan Anderson (a top 13% rated analyst) recently maintained her Strong Buy rating with a $33 price target following the company's strong quarterly results that showcased solid fundamentals and competitive positioning.
• DA Davidson also recently maintained its Strong Buy rating, highlighting the momentum following Nature's Sunshine's record-setting financial performance and beat on earnings estimates.
• Industry ranking context: NATR is currently the 2nd highest-rated stock in the Food industry, which has an Industry Rating of C, demonstrating significant outperformance relative to sector peers.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — our 115-factor review has identified NATR as a stock poised for future success and growth. 
• Component Grade highlights: Nature's Sunshine's strong financial health is reflected in its Component Grade of B for Financials and A for Sentiment. See the Component Grades here.

2. Neurocrine Biosciences (NASDAQ: NBIX)

Neurocrine Biosciences is turning heads on Wall Street with a powerhouse pipeline in neurological and psychiatric treatments — and the street's most elite analysts are lining up behind it after a string of clinical wins.

Zen Rating: B (Buy) — see full analysis

Recent Price: $130.71 — get current quote

Max 1-year forecast: $204.00

Why we're watching:

• Analyst support: NBIX commands exceptional Wall Street backing with 9 Strong Buy ratings, 5 Buy ratings, and 3 Hold ratings across 17 analysts, reflecting a Strong Buy consensus. See the ratings
• For example, Wolfe Research analyst Rudy Li (a top 2% rated analyst) initiated coverage with a Buy rating and $160 price target, emphasizing strong potential in Neurocrine's pipeline compared favorably against peers.
• Needham's Ami Fadia (a top 1% rated analyst), Wedbush's Laura Chico (a top 5% rated analyst), and Citigroup's Yigal Nochomovitz (a top 10% rated analyst) all maintain positive ratings, demonstrating the breadth of top-tier analyst support.
• The company's return on equity of 41.28% and analysts project strong double-digit EPS growth for next year, underscoring the company's financial momentum and growth trajectory.
• Industry ranking context: NBIX is currently the 11th highest-rated stock out of 58 (top 75%) in the Pharmaceutical industry, which has an Industry Rating of B.
• Zen Rating highlights: Buy (B) stocks average +19.88%/yr — our 115-factor analysis indicates NBIX has serious market-beating potential. 
• Neurocrine demonstrates exceptional financial strength with Component Grades including Financials at A (95th percentile), Value at A (70th percentile), and Growth at B (80th percentile). See all 7 Zen Component Grades here

3. Beachbody Company (NASDAQ: BODI)

Beachbody is staging one of the most dramatic comebacks in fitness — nine straight profitable quarters and the buzzy launch of P90X Generation Next have Wall Street taking notice of this once-written-off brand.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $11.73 — get current quote

Max 1-year forecast: $15.00

Why we're watching:

• Analyst support: We only track one analyst who rates BODI, but they are BULLISH. Susan Anderson of Canaccord Genuity maintains a Strong Buy rating and price target that suggests over 30% upside potential in the coming year. See the ratings
• Anderson highlighted management's effective transformation strategy that has delivered profitability for nine consecutive quarters.
• Improving fundamentals: The company reported a dramatic improvement in Q4 2025 with a loss per share of $0.71 versus a $5.04 loss in Q4 2024, while full-year 2025 loss per share improved to $0.41 from $10.51, demonstrating significant operational progress.
• Industry ranking context: BODI is currently the 3rd highest-rated stock in the Internet Content & Information industry, which has an Industry Rating of B. See more top-rated stocks in the industry here.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — BODI has skyrocketed 212.33% from its 52-week low of $3.38, a clear signal the market is buying into this comeback story.
• Among the Component Grades, BODI has above-average Bs in several key areas including Financials, Growth, and Sentiment. See all 7 Component Grades here.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.